Ctt Pharmaceutical Holdings Stock Performance
| CTTH Stock | USD 0.05 0 2.97% |
CTT Pharmaceutical holds a performance score of 4 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 4.45, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CTT Pharmaceutical will likely underperform. Use CTT Pharmaceutical value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on CTT Pharmaceutical.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in CTT Pharmaceutical Holdings are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly fragile basic indicators, CTT Pharmaceutical demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
CTT |
CTT Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 6.80 in CTT Pharmaceutical Holdings on September 13, 2024 and sell it today you would lose (1.90) from holding CTT Pharmaceutical Holdings or give up 27.94% of portfolio value over 90 days. CTT Pharmaceutical Holdings is currently generating 1.4835% in daily expected returns and assumes 25.1072% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than CTT, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CTT Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CTT Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CTT Pharmaceutical Holdings, and traders can use it to determine the average amount a CTT Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0591
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CTTH | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 25.11 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.48 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average CTT Pharmaceutical is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CTT Pharmaceutical by adding it to a well-diversified portfolio.
CTT Pharmaceutical Fundamentals Growth
CTT Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CTT Pharmaceutical, and CTT Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CTT Pink Sheet performance.
| Return On Equity | -4.49 | |||
| Return On Asset | -1.54 | |||
| Current Valuation | 18.87 M | |||
| Shares Outstanding | 21.32 M | |||
| Price To Earning | (3.00) X | |||
| Price To Book | 10.64 X | |||
| Revenue | 40 K | |||
| Cash And Equivalents | 32.12 K | |||
| Total Debt | 87.62 K | |||
| Debt To Equity | 0.12 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (145.16 K) | |||
| Earnings Per Share | (0.08) X | |||
| Total Asset | 186.54 K | |||
About CTT Pharmaceutical Performance
By evaluating CTT Pharmaceutical's fundamental ratios, stakeholders can gain valuable insights into CTT Pharmaceutical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CTT Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CTT Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. The company was formerly known as Mindesta Inc. and changed its name to CTT Pharmaceutical Holdings, Inc. in July 2015. Ctt Pharmaceutical is traded on OTC Exchange in the United States.Things to note about CTT Pharmaceutical performance evaluation
Checking the ongoing alerts about CTT Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CTT Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CTT Pharmaceutical is way too risky over 90 days horizon | |
| CTT Pharmaceutical has some characteristics of a very speculative penny stock | |
| CTT Pharmaceutical appears to be risky and price may revert if volatility continues | |
| CTT Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 40 K. Net Loss for the year was (1.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CTT Pharmaceutical Holdings currently holds about 32.12 K in cash with (145.16 K) of positive cash flow from operations. |
- Analyzing CTT Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CTT Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining CTT Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CTT Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CTT Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CTT Pharmaceutical's pink sheet. These opinions can provide insight into CTT Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CTT Pink Sheet analysis
When running CTT Pharmaceutical's price analysis, check to measure CTT Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CTT Pharmaceutical is operating at the current time. Most of CTT Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of CTT Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CTT Pharmaceutical's price. Additionally, you may evaluate how the addition of CTT Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world |